Michael D. Clayman, President and CEO at Flexion Therapeutics Inc (FLXN), sold 3,278 shares at $12.36 ($41K) on 2019-01-03, disclosed to the SEC on 2019-01-04.
Scheduled sale ($41k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| FLXN | BUY | 2019-05-13 | $100K | — | Filing → |
| FLXN | BUY | 2019-03-13 | $100K | — | Filing → |
| FLXN | BUY | 2018-11-13 | $86K | — | Filing → |